ACSL4 and Hepatic fibrosis: Previous studies have demonstrated the efficacy of abemaciclib in attenuating liver injury and liver fibrosis in a mouse model of nonalcoholic fatty liver disease by selectively inhibiting ACSL4 expression [21].